https://www.selleckchem.com/products/neo2734.html
The inclusion of tests specific to SARS-CoV-2 (such as RBD of spike protein) could overcome these limitations.The COVID-19 pandemic, caused by SARS-CoV-2, has led to substantial morbidity, mortality, and disruption globally. Cellular entry of SARS-CoV-2 is mediated by the viral spike protein, and affinity ligands to this surface protein have the potential for applications as antivirals and diagnostic reagents. Here, we describe the affinity selection of cyclic peptide ligands to the SARS-CoV-2 spike protein receptor binding domain (RBD)
Like
Comment
Share
